Thymidylate synthase genotyping is more predictive for therapy response than immunohistochemistry in patients with colon cancer
✍ Scribed by Marleen J. Gosens; Elna Moerland; Valery P. Lemmens; Harm T. Rutten; Ivonne Tan-Go; Adriaan J. van den Brule
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- French
- Weight
- 501 KB
- Volume
- 123
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Thymidylate synthase (TS) is a potentially valuable marker for therapy response since it is the molecular target of 5‐fluorouracil (5‐FU). TS can be analyzed at the DNA (gene polymorphisms and amplification) and protein level (immunohistochemistry). This study investigated the predictive role of TS at the DNA and protein levels in patients with N^+^ colon cancer (n = 38). Tumor and normal tissues were genotyped using PCR for variable number of tandem repeats (VNTR), a single nucleotide polymorphism (SNP) in the 3R allele and a 6 bp deletion (1494del6) in the TS gene. Tumor tissues were additionally analyzed for loss of heterozygosity (VNTR polymorphism). A newly developed real time PCR assay was used to detect the presence of TS gene amplifications in tumor tissues. VNTR analysis in normal tissue was significantly associated with distant tumor recurrence (8% for 2R/2R vs. 52% for patients carrying a 3R allele, p = 0.038) and cancer‐specific survival (p = 0.021). IHC was not found to be significantly associated with patients' outcome. No correlations between TS gene polymorphisms and IHC were found. However, TS gene amplification was correlated with a strong IHC staining intensity. In conclusion, this study indicates that DNA based analysis is more predictive for patients' outcome than TS IHC. © 2008 Wiley‐Liss, Inc.